Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin A Gartrell

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Investigational New Drugs|May 4, 2017
Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidenceDiego A Adrianzen Herrera, Sarah B Fleisig, Benjamin A Gartrell
Expert Review of Anticancer Therapy|December 21, 2012
Emerging personalized approaches for the management of advanced urothelial carcinomaChe-Kai Tsao, Benjamin A Gartrell, William K Oh, et al.
European Urology Focus|August 21, 2025
Temporal Trends and Socioeconomic Determinants of Cytoreductive Nephrectomy Utilization for Metastatic Renal Cell Carcinoma in the USAStepan M Esagian, Pavlos Msaouel, Jose A Karam, et al.
Skinmed|January 3, 2025
Novel Presentation of Lichenoid Dermatoses Preceding Bullous Pemphigoid Secondary to Immune Checkpoint Inhibitor TherapyLindsay M Pattison, Bahar Javdan, Pooja Srivastava, et al.
Frontiers in Oncology|May 16, 2018
Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent MalignanciesDiego Andres Adrianzen Herrera, Shlomit Goldberg-Stein, Alexander Sankin, et al.
Investigational New Drugs|September 14, 2020
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancerBenjamin A Gartrell, Mack Roach, Avi Retter, et al.
European Urology|May 28, 2013
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancerBenjamin A Gartrell, Robert E Coleman, Karim Fizazi, et al.
European Urology|July 9, 2015
Metastatic Prostate Cancer and the Bone: Significance and Therapeutic OptionsBenjamin A Gartrell, Robert Coleman, Eleni Efstathiou, et al.
American Journal of Cancer Research|February 10, 2022
Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studiesRushikesh Potdar, Benjamin A Gartrell, Robert Given, et al.
Targeted Oncology|July 16, 2013
Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysisBenjamin A Gartrell, Jian Ying, Shanthi Sivendran, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Investigational New Drugs|May 4, 2017
Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidenceDiego A Adrianzen Herrera, Sarah B Fleisig, Benjamin A Gartrell
Expert Review of Anticancer Therapy|December 21, 2012
Emerging personalized approaches for the management of advanced urothelial carcinomaChe-Kai Tsao, Benjamin A Gartrell, William K Oh, et al.
European Urology Focus|August 21, 2025
Temporal Trends and Socioeconomic Determinants of Cytoreductive Nephrectomy Utilization for Metastatic Renal Cell Carcinoma in the USAStepan M Esagian, Pavlos Msaouel, Jose A Karam, et al.
Skinmed|January 3, 2025
Novel Presentation of Lichenoid Dermatoses Preceding Bullous Pemphigoid Secondary to Immune Checkpoint Inhibitor TherapyLindsay M Pattison, Bahar Javdan, Pooja Srivastava, et al.
Frontiers in Oncology|May 16, 2018
Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent MalignanciesDiego Andres Adrianzen Herrera, Shlomit Goldberg-Stein, Alexander Sankin, et al.
Investigational New Drugs|September 14, 2020
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancerBenjamin A Gartrell, Mack Roach, Avi Retter, et al.
European Urology|May 28, 2013
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancerBenjamin A Gartrell, Robert E Coleman, Karim Fizazi, et al.
European Urology|July 9, 2015
Metastatic Prostate Cancer and the Bone: Significance and Therapeutic OptionsBenjamin A Gartrell, Robert Coleman, Eleni Efstathiou, et al.
American Journal of Cancer Research|February 10, 2022
Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studiesRushikesh Potdar, Benjamin A Gartrell, Robert Given, et al.
Targeted Oncology|July 16, 2013
Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysisBenjamin A Gartrell, Jian Ying, Shanthi Sivendran, et al.
Pageof 6